Skip to search formSkip to main contentSkip to account menu

3'-deamino-3'-hydroxydoxorubicin

Known as: 3-DHD, 5,12-Naphthacenedione, 10-((2,6-dideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-, hydroxyrubicin 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Objective: This phase Ia study was designed to assess the pharmacokinetic (PK) characters of free vincristine (F-VCR, refer to as… 
2007
2007
N-Benzyladriamycin-14-valerate (AD 198) is one of several novel anthracycline protein kinase C (PKC)-activating agents developed… 
2001
2001
Cells that acquire multidrug resistance (MDR) are characterized by a decreased accumulation of a variety of drugs. In addition… 
Highly Cited
1997
Highly Cited
1997
The knowledge about molecular factors driving simple ligand-DNA interactions is still limited. The aim of the present study was… 
1994
1994
In vivo effectiveness of doxorubicin remains restricted due to toxicity and drug resistance. Hydroxyrubicin is a synthetic analog… 
Highly Cited
1993
Highly Cited
1993
Hydroxyrubicin, a synthetic doxorubicin analog in which the basic amino group at C-3' is replaced by a hydroxyl group, was used… 
1984
1984
Two successful routes have been developed for preparation of 3'-deamino-3'-hydroxydoxorubicin (11), based on protection of the 14… 
1984
1984
3'-Deamino-4'-epi-3'-hydroxy-daunorubicin (11) and -doxorubicin (14) have been synthesized. In the in vivo murine P-388…